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Abstract
Reactive gliosis is a hallmark of many retinal neurodegenerative conditions, including glaucoma. Although a majority of
studies to date have concentrated on reactive gliosis in the optic nerve head, very few studies have been initiated to
investigate the role of reactive gliosis in the retina. We have previously shown that reactive glial cells synthesize elevated
levels of proteases, and these proteases, in turn, promote the death of retinal ganglion cells (RGCs). In this investigation, we
have used two glial toxins to inhibit reactive gliosis and have evaluated their effect on protease-mediated death of RGCs.
Kainic acid was injected into the vitreous humor of C57BL/6 mice to induce reactive gliosis and death of RGCs. C57BL/6 mice
were also treated with glial toxins, alpha-aminoadipic acid (AAA) or Neurostatin, along with KA. Reactive gliosis was
assessed by immunostaining of retinal cross sections and retinal flat-mounts with glial fibrillary acidic protein (GFAP) and
vimentin antibodies. Apoptotic cell death was assessed by TUNEL assays. Loss of RGCs was determined by immunostaining
of flat-mounted retinas with Brn3a antibodies. Proteolytic activities of matrix metalloproteinase-9 (MMP-9), tissue
plasminogen activator (tPA), and urokinase plasminogen activator (uPA) were assessed by zymography assays. GFAP-
immunoreactivity indicated that KA induced reactive gliosis in both retinal astrocytes and in Muller cells. AAA alone or in
combination with KA decreased GFAP and vimentin-immunoreactivity in Mller cells, but not in astrocytes. In addition AAA
failed to decrease KA-mediated protease levels and apoptotic death of RGCs. In contrast, Neurostatin either alone or in
combination with KA, decreased reactive gliosis in both astrocytes and Mller cells. Furthermore, Neurostatin decreased
protease levels and prevented apoptotic death of RGCs. Our findings, for the first time, indicate that inhibition of reactive
gliosis decreases protease levels in the retina, prevents apoptotic death of retinal neurons, and provides substantial
neuroprotection.
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Introduction
Astrocytes present in the central nervous system, retina, and
optic nerve head were initially thought to be bystander cells, but
emerging studies indicate that they play important roles, including
regulation of ionic balance, neurotransmission, synaptic plasticity,
and neurodegeneration [1,2,3]. In the eye, two types of astrocytes
are present: type I astrocytes that express GFAP and connexin-43,
and type II astrocytes that express GFAP, but not connexin-43
[4,5,6]. Type I astrocytes are further divided into type Ia and type
Ib. Type Ia astrocytes are present in the optic nerve head, while
type Ib astrocytes are present in the inner limiting membrane of
the retina [7]. Interestingly, both types of quiescent astrocytes
become reactive in response to various stimuli, including elevated
intraocular pressure, excitotoxicity, and retinal ischemia to name a
few [8]. When astrocytes become reactive they proliferate and
exhibit enlarged soma, thickened astrocytic processes, and
increased GFAP-immunoreactivity. In the eye, whether astrocytes
become proliferative or not is debatable since a study on an animal
model for spontaneous glaucoma reported non-proliferative gliosis
[9], while investigations using an induced model of rat glaucoma
reported proliferative gliosis [10,11]. Nonetheless, reactive glial
cells express various inflammatory cytokines, including TNF-a
[12], IL-1b [13], and endothelin-1 [14,15], and promote the death
of RGCs.
While a number of studies have reported that reactivated type
Ia astrocytes in the optic nerve head promote damage to the
axons [3,7,8], the role of type Ib astrocytes in the death of RGCs
has not been explored further. In this context, by employing
animal models related to glaucoma, such as retinal ischemia [16]
and excitotoxicity [17,18,19], we have previously reported that
astrocytes become reactive, synthesize elevated levels of matrix
metalloproteinase-9 (MMP-9) and urokinase plasminogen acti-
vator (uPA), and promote the death of RGCs by degrading
extracellular matrix present in the ganglion cell layer [16,19]. In
addition, we have reported that RGCs undergoing degeneration
release intracellular tissue plasminogen activator (tPA) and
exacerbate retinal damage [19]. Based on these studies, we
have hypothesized that inhibition of reactive gliosis reduces
protease levels in the retina and prevents protease-mediated
death of RGCs. To test this hypothesis, we have employed an
established model of excitotoxicity (induced by kainic acid) in
C57BL/6 animals and investigated the effect of two glial toxins,
alpha-aminoadipic acid (AAA) [20,21,22] and Neurostatin
(Disialoganglioside-GD1b) [23,24] on protease levels and death
of RGCs.
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18305In this study, we report that excitotoxicity induces reactive
gliosis both in astrocytes and Mller cells. AAA does not decrease
excitotoxicity-mediated reactive gliosis or levels of proteases, and
does not inhibit the death of RGCs. In contrast, Neurostatin
inhibits excitotoxicity-mediated reactive gliosis, decreases protease
levels, and attenuates apoptotic death of RGCs.
Results
KA induces reactive gliosis in the retina
To investigate the effect of KA on reactive gliosis, C57BL/6
mice were treated with intravitreal injections of PBS (1 uL) or KA
(10 nM/1 uL). We chose 10 nM KA since between10–20 nM,
KA causes significant loss of RGCs within 72 h [19]. At the end of
24, 48, and 72 h after injection, eyes were enucleated, and fixed in
4% paraformaldehyde. Retinas were then processed for flat-
mounted retinas or for radial sections. Flat-mounts were
immunostained with antibodies against GFAP, and radial sections
were immunostained with antibodies against GFAP and vimentin.
Results presented in Figure 1 indicate that when compared to
PBS-treated retinas, astrocytes in KA-treated retinas exhibited
enlarged soma, thickened astrocytic processes, and increased
GFAP-immunoreactivity in a time-dependent manner (top panel).
In addition, when radial sections from KA-treated retinas were
observed, immunoreactivity was increased in both astrocytes and
Mller cells (bottom panel).
AAA does not inhibit reactive gliosis of astrocytes
To determine whether a known glial toxin, AAA, reduces KA-
induced reactive gliosis, animals were treated with PBS, KA
(10 nM), and KA plus AAA (100 ug/1 uL). A number of different
concentrations, ranging from 25 ug to 300 ug AAA, were injected
into the vitreous humor to determine an optimum dose. We found
that ,100 ug AAA did not inhibit reactive gliosis, while .100 ug
AAA caused severe damage to the retina, consistent with previous
reports (data not shown) [21]. Therefore, we chose 100 ug AAA
for further experiments.
At the end of 24, 48, and 72 h after injection, flat-mounted
retinas were immunostained with antibodies against GFAP, and
radial sections were immunostained with antibodies against GFAP
and vimentin. Results presented in Figure 2 indicate that when
compared to PBS-treated retinas, astrocytes in KA-treated retinas
exhibited reactive gliosis (top panel), consistent with results
presented in Figure 1. When flat-mounted retinas were compared,
GFAP-immunoreactivity was not decreased in KA plus AAA-
treated retinas. In addition, when radial sections were compared
between KA and KA plus AAA-treated retinas, GFAP- and
vimentin-immunoreactivity was reduced in Muller cells, but not in
astrocytes. Furthermore, AAA alone did not decrease GFAP
immunoreactivity in astrocytes (Figure 3).
AAA does not reduce KA-mediated protease levels in the
retina
We previously showed that KA induces MMP-9 and uPA levels
in astrocytes and tPA levels in RGCs [19], and elevated levels of
these proteases promote the death of RGCs. Therefore, to
determine the effect of AAA on protease levels, animals were
treated with KA, AAA, or KA plus AAA. At the end of 24, 48, and
72 h after treatment, retinal proteins were extracted and
zymography assays were performed by using aliquots containing
an equal amount of protein (50 ug). Gelatin and plasminogen/
fibrinogen zymography assays (Figure 4A) and quantitation of
protease activity (Figure 4B) indicate that a low level of MMP-9
and tPA was expressed constitutively in retinal proteins extracted
Figure 1. KA activates glial cells in the retina. C57BL/6 mice (n=6) were treated by intravitreal injection of PBS or KA (10 nM). At 24, 48 and 72 h
after injection, glial cell activation was assessed by immunostaining retinal flat mounts with antibodies against GFAP (top panel) or retinal cross
sections (lower panel) with antibodies against GFAP (green fluorescence) and vimentin (red fluorescence); blue indicates nuclei. Immunofluorescent
staining indicates that KA increases GFAP-immunoreactivity in both astrocytes and Mller cells. All images were acquired at 40x magnification.
doi:10.1371/journal.pone.0018305.g001
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contrast, MMP-9, tPA, as well as uPA levels (completely absent in
PBS-treated retinas) were elevated in animals treated with KA at
24, 48, and 72 h after the treatment. Furthermore, AAA alone did
not affect MMP-9 and tPA levels. Consistent with our previous
findings, immunostaining analysis indicated that astrocytes
expressed MMP-9 and uPA, while RGCs expressed tPA (data
not shown).
AAA does not reduce apoptotic cell death
To determine whether an up-regulation in proteases (induced
by KA) observed in Figure 4 promotes apoptotic death of RGCs,
Figure 2. AAA decreases GFAP expression in Muller cells, but not in astrocytes. C57BL/6 mice (n=6) were treated by intravitreal injection
of PBS, KA (10 nM), or KA plus AAA (100 ug). At 24, 48 and 72 h after injection, glial cell activation was observed by immunostaining retinal flat
mounts with antibodies against GFAP (top panel) or retinal cross sections (lower panel) with antibodies against GFAP (green fluorescence) and
vimentin (red fluorescence). Retinal cross sections were also counterstained with DAPI (blue). Immunostaining results indicate that KA induces GFAP-
immunoreactivity both in astrocytes (top panel) and Mller cells (lower panel). Results from radial sections indicate that AAA decreases KA-induced
GFAP-immunoreactivity in Mller cells, but not in astrocytes. All images were acquired at 406magnification.
doi:10.1371/journal.pone.0018305.g002
Figure 3. AAA alone does not inhibit GFAP expression in astrocytes. C57BL/6 mice (n=6) were treated by intravitreal injection of PBS or AAA
(100 ug). At 24, 48 and 72 h after injection, glial cell activation was assessed by immunostaining retinal flat mounts with antibodies against GFAP (top
panel), retinal cross sections (lower panel) with antibodies against GFAP (green fluorescence) and vimentin (red fluorescence). Retinal cross sections
were counterstained with DAPI to identify the nuclei (blue). Immunostaining results from retinal flat mounts indicate that AAA does not inhibit GFAP
expression in astrocytes. Results from cross sections indicate that AAA inhibits vimentin expression in Mller cells, but does not inhibit GFAP
expression in astrocytes (lower panel). All images were acquired at 406magnification.
doi:10.1371/journal.pone.0018305.g003
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24, 48, and 72 h after the treatment, radial sections were subjected
to TUNEL assays. TUNEL assays (Figure 5) indicated that KA
promotes apoptotic death of cells in the ganglion cell layer at 24 h,
and in both inner nuclear layer and outer nuclear layers at
subsequent time periods. In addition, AAA failed to reduce KA-
induced cell death at all time points tested. No TUNEL-positive
cells were observed in retinas treated with PBS or AAA.
AAA does not reduce KA-mediated loss of RGCs
To determine the effect of AAA on KA-induced loss of RGCs,
animals were treated with PBS, AAA, and KA plus AAA. At 24,
48, and 72 h after the treatment, flat-mounted retinas were
immunostained with antibodies against Brn3a, a marker for
RGCs. When comparison was made between PBS and KA
treatment, the density of Brn3a-positive RGCs was dramatically
reduced in KA-treated retinas (Figure 6A), but not in PBS-treated
Figure 4. AAA does not inhibit KA-induced protease expression. C57BL/6 mice (n=6) were treated by intravitreal injection of PBS, KA, AAA,
or KA plus AAA. At 24, 48 and 72 h after injection, proteins were extracted from the retinas, and aliquots containing an equal amount of protein
(50 ug) were subjected to zymography assays (A). The areas cleared by proteases were scanned by a densitometer and results from three
independent experiments were shown as arbitrary units (B). The assays indicate that a low level of MMP-9 and tPA were expressed constitutively in
the retinas treated with PBS or AAA at all time points tested. In contrast, KA increased not only MMP-9 and tPA levels, but also uPA levels, which were
absent in PBS and AAA-treated retinas. Furthermore, AAA failed to decrease the KA-mediated increase in MMP-9, tPA, and uPA levels at all time points
tested. *, **, *** p,0.05, compared to untreated or AAA-treated retinas.
doi:10.1371/journal.pone.0018305.g004
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RGCs was also decreased in KA and AAA-treated retinas; AAA
alone did not decrease the density of Brn3a-positive cells.
Quantitative analysis (Figure 6B) indicated that the number of
Brn3a-positive RGCs was reduced in KA-treated retinas by
,45%, 71%, and 95% (p,0.05) at 24, 48 and 72 h, respectively.
The number of Brn3a-positive RGCs was also reduced in KA and
AAA-treated retinas by ,49%, 80%, and 95% (p,0.05) at 24, 48
and 72 h, respectively. AAA alone did not decrease Brn3a-positive
cells at all the time points tested.
Neurostatin inhibits reactive gliosis in the retina
Since AAA failed to inhibit reactive gliosis and the death of
RGCs, we used a second gliotoxin, Neurostatin, to investigate its
effect on activation of glial cells. Animals were treated with PBS,
KA,orKAplusNeurostatin(5 mM/1 uL),andattheendof24, 48,
and 72 h after treatment, GFAP expression was assessed by
immunostaining of flat-mounted retinas with GFAP and radial
sections with GFAP and vimentin. Based on a number of
preliminary experiments using a range of Neurostatin concentra-
tions (250 nM to 10 mM), we found that ,5 mM Neurostatin did
not inhibit reactive gliosis, whereas .5 mM had no better effect
than 5 mM Neurostatin (data not shown). Therefore, we chose
5 mM Neurostatin to determine its effect on activation of glial cells.
At 24, 48, and 72 h after injection, flat-mounted retinas were
immunostained with antibodies against GFAP, and radial sections
were immunostained with antibodies against GFAP and vimentin.
Results presented in Figure 7 indicated that when compared to PBS-
Figure 5. Increased levels of tPA, uPA, and MMP-9 correlate with apoptotic cell death in the retina. C57BL/6 mice (n=6) were treated by
intravitreal injection of PBS, KA (10 nM), AAA (100 ug), and KA plus AAA. At 24, 48 and 72 h after injection, apoptotic cell death was determined by
TUNEL assay. The results indicate that KA induces apoptotic death of cells initially in the ganglion cell layer and subsequently in the inner and outer
nuclear layers. TUNEL-positive cells were absent both in PBS and AAA-treated retinas. Furthermore, the TUNEL assays indicate that AAA does not
inhibit KA-induced apoptosis. All images were acquired at 406magnification.
doi:10.1371/journal.pone.0018305.g005
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gliosis as expected (top panel). However, when comparison was
made between KA and KA plus Neurostatin-treated retinas,
astrocytes exhibited a shrunken cell soma and expressed reduced
GFAP-immunoreactivity after KA plus Neurostatin treatment. In
addition, when compared between KA and KA plus Neurostatin-
treated retinas, GFAP-immunoreactivity was reduced both in
astrocytes and Mller cells after KA plus Neurostatin treatment.
To determine the effect of Neurostatin alone on reactive gliosis,
animals were treated with PBS or PBS plus Neurostatin. At the
end of 24, 48, and 72 h after injections flat-mounted retinas were
immunostained with antibodies against GFAP, and radial sections
were immunostained with antibodies against GFAP and vimentin
(Figure 8). When comparison was made between PBS-treated and
Neurostatin-treated retinas, astrocytes again exhibited shrunken
cell soma and reduced GFAP-expression after Neurostatin
treatment (top panel). Immunostaining analysis of radial sections
indicated that Neurostatin alone reduces GFAP-immunoreactivity
both in Mller cells and astrocytes at all the time points tested.
Neurostatin reduces KA-mediated protease levels in the
retina
Since the above results indicated that Neurostatin reduces
activation of astrocytes, and astrocytes are responsible for elevated
levels of MMP-9 and uPA in the retina [16,19], animals were
treated with PBS, KA, or KA plus Neurostatin. At the end of 24,
48, and 72 h after treatment, zymography assays were performed
by using aliquots containing an equal amount of protein (50 ug)
extracted from the retinas. Gelatin zymography assays (Figure 9A)
and quantitation of protease activity (Figure 9B) indicated that a
low level of MMP-9 and tPA was expressed constitutively in retinal
proteins extracted from animals treated with PBS, at all time
points tested. MMP-9, tPA, as well as uPA levels (absent in PBS-
treated retinas) were elevated in animals treated with KA at 24, 48,
and 72 h after the treatement. In contrast, Neurostatin reduced
MMP-9, tPA, and uPA levels in the retinas at all time points
tested. When compared to PBS-treated retinas, Neurostain alone
reduced MMP-9 levels observed constitutively in PBS-treated
retinas. Consistent with our previous findings, immunostaining
Figure 6. AAA does not inhibit KA-induced loss of RGCs. C57BL/6 mice were treated by intravitreal injection of PBS, KA (10 nM), AAA (100 ug),
and KA plus AAA. At 24, 48, and 72 h after treatment, loss of RGCs was determined by immunofluorescent staining of retinal flat mounts with
antibodies against Brn3a (left panel). Immunofluorescent staining and quantification of cell loss (right panel) indicate that while Brn3a-positive RGCs
remained similar in PBS and AAA-treated animals, Brn3a-positive RGCs were reduced significantly in animals treated with KA (*, p,0.05) or KA plus
AAA (**, p,0.05). All images were acquired at 406magnification.
doi:10.1371/journal.pone.0018305.g006
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whereas RGCs expressed tPA (data not shown).
Neurostatin inhibits apoptotic cell death in the retina
Since Neurostatin reduced KA-mediated protease levels,
animals were treated with PBS, Neurostatin, KA, and KA plus
Neurostatin to determine whether reduced levels of proteases
might attenuate apoptotic death of RGCs. At 24, 48, and 72 h
after the treatment, radial sections were prepared and assessed for
apoptotic death by TUNEL assays. TUNEL assays (Figure 10)
indicate that KA promoted apoptotic death of cells in the ganglion
cell layer at 24 h, and in both the inner nuclear layer and outer
nuclear layer at 48 and 72 h as expected. In contrast, apoptotic
cell death was dramatically reduced in retinas treated with KA and
Neurostatin. TUNEL-positive cells were not observed in retinas
when treated with PBS or Neurostatin.
Neurostatin inhibits KA-mediated loss of RGCs
To determine whether Neurostatin inhibits KA-induced RGC
loss, animals were treated with PBS, Neurostatin, and KA plus
Neurostatin. At 24, 48, and 72 h after the treatment, flat-mounted
retinas were immunostained with antibodies against Brn3a. When
a comparison was made between PBS and KA, the density of
Brn3a-positive RGCs was reduced drastically in KA-treated
retinas (Figure 11A). In contrast, when compared to PBS, the
density of Brn3a-positive RGCs was not decreased in KA and
Neurostatin-treated retinas. In addition, Neurostatin alone had no
effect on the density of Brn3a-positive cells. Quantitative analysis
(Figure 11B) indicated that the number of Brn3a-positive RGCs in
KA-treated retinas was reduced by ,45%, 71%, and 94%
(p,0.05) at 24, 48 and 72 h, respectively. In contrast, when retinas
were treated with KA and Neurostatin, the number of Brn3a-
positive RGCs was reduced only by ,14–16% (p,0.05).
Neurostatin alone did not decrease Brn3a-positive cells at all time
points tested.
Discussion
Neuroectodermally derived astrocytes differ from neurons by
being quiescent and non-excitable. Astrocytes in the retina (type
Ib) are normally found in the nerve fiber layer, whereas astrocytes
in the optic nerve head (type Ia) are interspersed between the
plates of lamina cribrosa [25]. Astrocytes may play dual roles:
beneficial and degenerative. Some of the beneficial roles include
neurotrophic support, enhanced mechanical support for degener-
ating axons, and maintenance of the blood-retinal barrier [26]. In
response to injury or disease, the same astrocytes express a number
of proteins that compromise the integrity of blood-retinal barrier,
up-regulate the expression of various genes related to cytokines,
chemokines, and the complement cascade, and promote retinal
degeneration [27,28]. Interestingly, in the optic nerve head,
reactive astrocytes express many new extracellular matrix proteins
such as laminin, tenascin C, elastin, and proteoglycans [7,8,29]. In
contrast, reactive astrocytes in the retina express increased levels of
MMP-9 and uPA [19], degrade the extracellular matrix in the
inner limiting membrane, and promote death of RGCs by
detachment-induced apoptosis [17,30]. In support of the detri-
mental role of astrocytes, we and others have shown that a
deficiency of either MMP-9 [30] or tPA [31] attenuates RGC
death significantly.
Since our previous studies indicated that reactive astrocytes play
a major role in protease-mediated death of RGCs, we hypothe-
sized that inhibition of reactive gliosis down-regulates the
expression of detrimental proteases and prevents RGC loss. To
investigate this hypothesis, we induced RGC loss in C57BL/6
mice by intravitreal injections of a non-NMDA-type glutamate
receptor agonist, kainic acid (KA), along with two glial toxins,
AAA and Neurostatin, which are known to prevent reactive gliosis.
We noticed that these two glial toxins exert different inhibitory
activities on astrocytes and Mller cells. First, AAA inhibited the
activation of Mller cells, but not astrocytes. Second, since
astrocytes are responsible for the expression of proteases and
Figure 7. Neurostatin down-regulates GFAP expression in astrocytes. C57BL/6 mice (n=6) were treated by intravitreal injection of
PBS, KA (10 nM), or KA plus Neurostatin (5 mM). At 24, 48 and 72 h after injection, glial cell activation was observed by immunostaining of
retinal flat mounts with antibodies against GFAP (top panel) or retinal cross sections (lower panel) with antibodies against GFAP (green
fluorescence) and vimentin (red fluorescence). Retinal cross sections were also counterstained with DAPI (blue). Immunostaining results indicate
that KA induces GFAP-immunoreactivity in both astrocytes (top panel) and Mller cells (lower panel). Results from radial sections indicate that
Neurostatin decreases KA-mediated GFAP-immunoreactivity not only in astrocytes, but also in Mller cells. All images were acquired at 406
magnification.
doi:10.1371/journal.pone.0018305.g007
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were not reduced. Third, since protease levels were not reduced in
the retinas, RGC death was also not inhibited.
In contrast, Neurostatin inhibited the activation of not only
Mller cells, but also inhibited the activation of astrocytes.
Interestingly, since Neurostatin inhibited the activation of
astrocytes, which are responsible for proteases, protease levels
were reduced significantly in Neurostatin-treated retinas. In
addition, due to low levels of proteases, RGC death was inhibited
significantly in Neurostatin-treated retinas. These results, for the
first time, suggest that Neurostatin may be useful as an adjuvant
therapeutic agent to inhibit activation of glial cells and to prevent
RGC death not only under excitotoxic conditions, but also in
glaucoma in which excitotoxicity has been implicated.
Until now, it was unclear whether reactive gliosis can be
reversed in retinal degenerative conditions, including glaucoma.
Results presented in this study, at least in an excitotoxicity model
of retinal degeneration, suggest that reactive gliosis is reversible,
and reversal of reactive gliosis is neuroprotective. In a broader
picture, use of Neurostatin seems to be advantageous because one
can down-regulate three proteases by inhibiting reactive gliosis
selectively, rather than by using three different protease inhibitors
to prevent RGC loss as we have shown in previous studies [17,19].
In the future, it would be worthwhile to investigate whether a
topical application rather than invasive application of Neurostatin
would prevent reactive gliosis to prevent RGC loss in retinal
neurodegenerative conditions, including glaucoma. In addition, it
would be worthwhile to investigate the effect of Neurostatin in a
slow retinal degenerative model such as glaucoma.
Materials and Methods
Materials
The following materials were obtained for use in this study:
human glu-plasminogen (product 410) and human fibrinogen
(product 431) from American Diagnostica (Stamford, CT); gelatin
from Biorad laboratories (Hercules, CA); alpha-aminoadipic acid
(AAA) and Neurostatin (Disialoganglioside-GD1b) from Sigma
Chemical Company (St. Louis, MO); antibodies against Brn3a
and vimentin from Santa Cruz Biotechnology (Santa Cruz, CA);
antibodies against glial fibrillary acidic protein (GFAP) from Dako
North America Inc., (Carpinteria, CA); secondary antibodies
conjugated to AlexaFlour-568 and 488 from Invitrogen (Carlsbad,
CA); and TUNEL kit from Roche Biochemicals.
Intravitreal Injections
All experiments on animals were performed under general
anesthesia according to the protocols approved by Oakland
University’s Animal Care and Use Committee (approval ID
10011-R2), and according to the ARVO Statement for Use of
Animals in Ophthalmic and Vision Research. Normal adult
C57BL/6 mice (6–8 week-old; Charles River Breeding Labs,
Wilmington, MA, USA) were anesthetized by an intraperitoneal
injection of 1.25% avertin (2,2,2-tribromoethanol in tert-amyl
alcohol; 17 uL/g body weight). After instilling a drop of topical
anesthetic agent (proparacaine), PBS (2 uL), KA (10 nM/1 uL),
AAA (100 ug/1 uL), or Neurostatin (5 mM/1 uL) were injected
into the vitreous humor by using a NanoFil syringe (World
Precision Instruments, Sarasota, FL) equipped with a 36 gauge
beveled needle.
Extraction of total proteins from retinas
At 24, 48, and 72 hours after intravitreal injection, animals were
euthanized with an overdose of CO2 and their eyes were
enucleated. Enucleated eyes were cut in half at the equator and
the lenses removed. Retinas were carefully peeled off with forceps
and washed three times with PBS (pH 7.4) to remove vitreous that
may have adhered to the retina. Four to six retinas each were
placed in Eppendorf tubes (Eppendorf, Fremont, CA) containing
40 uL extraction buffer (1% nonidet-P40, 20 mM Tris-HCl,
150 mM NaCl, and 1 mM Na3VO4 [pH 7.4]) and the tissues
Figure 8. Neurostatin alone reduces GFAP expression. C57BL/6 mice (n=6) were treated by intravitreal injection of PBS, KA (10 nM), or KA
plus Neurostatin (5 mM). At 24, 48 and 72 h after injection, retinal flat mounts were immunostained with antibodies against GFAP (top panel) and
retinal cross sections (lower panel) with antibodies against GFAP (green) and vimentin (red fluorescence). Retinal cross sections were also
counterstained with DAPI (blue). Immunostaining results indicate that Neurostatin alone reduces GFAP expression in both astrocytes and Mller cells.
All images were acquired at 406magnification.
doi:10.1371/journal.pone.0018305.g008
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10,000 rpm for 5 minutes at 4uC, and supernatants collected.
The protein concentration in the supernatants was determined by
using a commercial assay Kit (Bio-Rad Laboratories, Hercules,
CA).
Zymography Assays
Proteolytic activity of MMP-9, tPA, and uPA was determined
by substrate zymography according to methods described
previously [19,30,32]. Briefly, aliquots containing equal amounts
of retinal protein extracts (50 ug total protein) were mixed with 4x
SDS gel-loading buffer and the samples were loaded (without
reduction or heating) onto 10% SDS polyacrylamide gels
containing gelatin (2.6 mg/mL) to detect MMP-9, and fibrinogen
(5.5 mg/mL) and plasminogen (50 ug/mL) to detect uPA and
tPA. After electrophoresis, gels were washed three times with 2.5%
Triton X-100 (15 minutes each time), placed in 0.1 M glycine
buffer (pH 8.0 [for tPA and uPA]) or in 10 mM calcium chloride
buffer (pH 7.4 [for MMP-9]), and incubated overnight at 37uCt o
allow proteolysis of the substrates in the gels. After overnight
Figure 9. Neurostatin reduces KA-induced protease levels in the retina. C57BL/6 mice (n=6) were treated by intravitreal injection of PBS,
KA, Neurostatin, and KA plus Neurostatin. At 24, 48 and 72 h after injection, proteins were extracted from the retinas and aliquots containing an equal
amount of protein (50 ug) were subjected to zymography assays (A). The areas cleared by proteases were scanned by a densitometer and results
from three independent experiments were represented as arbitrary units (B). The assays indicate that low levels of MMP-9 and tPA were expressed
constitutively in retinas treated with PBS alone. KA increased the levels not only of MMP-9 and tPA, but also of uPA levels, which were absent in PBS
or Neurostatin-treated retinas at all time points tested. In contrast, when animals were treated with Neurostatin and KA, levels of all three proteases
were reduced considerably. *p,0.05, compared to Neurostatin-treated and **p,0.05 compared to KA-treated retinas.
doi:10.1371/journal.pone.0018305.g009
Inhibition of Reactive Gliosis Attenuates RGC Death
PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e18305incubation, gels were stained with 0.25% Coomassie brilliant blue
R250 (for 4 min) and de-stained with a solution containing 50%
methanol and 10% acetic acid in deionized water. Samples
containing standard recombinant MMP-9, tPA, or uPA were
electrophoresed for comparison (data not shown).
Immunohistochemistry
Radial sections. Eyes enucleated at24,48,and 72 hoursafter
injection were fixed in 4% paraformaldehyde for 1 h at room
temperature and embedded in OCT compound (Sakura Finetek
USA, Torrance, CA). Ten micron-thick radial sections were
prepared by using a cryostat and placed onto super-frost plus
slides (Fisher Scientific, Pittsburgh, PA). Sections were
immunostained by using antibodies against GFAP and vimentin
(1:100 dilution in PBS) for 1 h at room temperature. Sections were
washed three times with PBS and incubated with secondary
antibodies conjugated to AlexaFluor-568 or Alexafluor-488 for 1 h
at room temperature and washed three times with PBS. After
counterstaining with DAPI (diamidino-2-phenylindole), sections
were mounted with a coverslip. Immunoreactivity of GFAP and
vimentin was assessed by observing the sections under a Zeiss
microscope equipped with epifluorescence. Digitized images were
obtained by using a Zeiss camera and the images were processed
and compiled by usingAdobe Photoshop Software, versions 5.5and
7.0 (Adobe system Incorporated, CA).
Flat-mounted Retinas.. Eyes enucleated at 24, 48, and
72 hours after injection were fixed in 4% paraformaldehyde for
30 min at room temperature. Corneas and lenses were removed
and the remaining eyecups were incubated in 4%
paraformaldehyde for another 30 min. Retinas were peeled off
carefully, washed three times with PBS, and ganglion cells
remaining in the retinas were identified according to methods
described by Nadal-Nicolas et al.[33] Briefly, whole retinas were
permeabilized in 0.5% Triton-X100 (in PBS) for 15 minutes at
room temperature. Retinas were washed three times with PBS and
incubated overnight at 4uC in polyclonal antibodies against Brn3a
(1:100 dilution in blocking buffer [(2% bovine serum albumin, 2%
Triton-X100, and PBS]). After overnight incubation, retinas were
Figure 10. Neurostatin-mediated decrease in protease levels correlate with reduced apoptotic cell death. C57BL/6 mice (n=6) were
treated by intravitreal injection of PBS, KA (10 nM), Neurostatin (5 mM), and KA plus Neurostatin. At 24, 48 and 72 h after injection, apoptotic cell
death was determined by TUNEL assay. The assay indicate that KA induces apoptotic death of cells initially in the ganglion cell layer and subsequently
in the inner and outer nuclear layers. TUNEL-positive cells were absent both in PBS and Neurostatin-treated retinas. Furthermore, only a few TUNEL-
positive cells were present in the ganglion cell layer (GCL), and in the inner (INL) and outer nuclear layers (ONL), indicating that Neurostatin not only
reduces protease levels, but also attenuates KA-induced apoptosis. All images were acquired at 406magnification.
doi:10.1371/journal.pone.0018305.g010
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temperature in secondary antibodies conjugated to AlexaFlour-
568 (1:200 dilution in blocking buffer). Subsequently, retinas were
washed three times with PBS and mounted onto slides, vitreous
side facing upwards. Brn3a-positive RGCs in whole mounted
retinas were assessed by observing flat mounted retinas under a
Zeiss microscope equipped with epifluorescence. Digitized images
were obtained by using a Zeiss camera and the images were
processed and compiled using Adobe Photoshop Software,
versions 5.5 and 7.0 (Adobe Systems Incorporated, CA). The
total number of Brn3a-positive cells in the retinas, located
approximately at the same distance from the optic disk (7200 sq.
microns, 406 magnification) was quantitated by using Scion
Image analysis software (Scion Corp., Frederick, MD). For
quantitative analysis, Brn3a-positive cells were counted in four to
six microscope fields of identical size located at approximately the
same distance from the optic disc. Statistical significance was
analyzed using a nonparametric Newman-Keuls analog procedure
(GB-Stat Software, Dynamic Microsystems, Silver Spring, MD)
and expressed as the mean +/2SEM.
Apoptotic cell death
Apoptotic cell death in retinal cross sections was determined
using a commercially available kit according to methods described
previously [19].
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Figure 11. Neurostatin attenuates KA-induced ganglion cell loss. C57BL/6 mice were treated by intravitreal injection of PBS, KA (10 nM),
Neurostatin (5 mM), or KA plus Neurostatin. At 24, 48, and 72 h after the treatment, loss of RGCs was determined by immunofluorescent staining of
retinal flat mounts with antibodies against Brn3a (left panel). Immunofluorescent staining and quantification of cell loss (right panel) indicate that
while Brn3a-positive RGCs remained similar in both PBS and Neurostatin-treated animals, Brn3a-positive RGCs were decreased significantly in KA-
treated retinas (+,p ,0.05). In contrast, Brn3a-Positive RGC loss was inhibited significantly (++,P ,0.05) in animals treated with KA plus Neurostatin.
All images were acquired at 406magnification.
doi:10.1371/journal.pone.0018305.g011
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